Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
HL.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XCDNYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XCDNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.44.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.44.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EG.2.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
EG.2.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.37NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.37NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.45.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.45.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FP.4NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FP.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.102NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.5.102NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FK.1.3NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FK.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GN.5NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
GN.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.31NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.31NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.13.3NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.13.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.2.2.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.2.2.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.25NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.25NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.33NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.33NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.29NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.29NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EG.13NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
EG.13NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GP.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
GP.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
KP.4.2.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
KP.4.2.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
KP.3.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
KP.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
MC.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
MC.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
LB.1.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
LB.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
LP.1.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
LP.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.1.50.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
JN.1.50.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
MA.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
MA.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
KP.3.1.4NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used